Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MPB
|
|||
| Former ID |
DIB009821
|
|||
| Drug Name |
Bevirimat
|
|||
| Synonyms |
DSB; Bevirimat dimeglumine; DSB 2NMG; MPC-4326; PA-457; PA-103001-01; PA-103001-04; PA-457 di-NMG; Viral maturation inhibitor (HIV), Myrexis; Viral maturation inhibitor (HIV), Myriad; Viral maturation inhibitor (HIV), Panacos; YK-FH-312; 3-O-(3' 3'-dimethylsuccinyl)-betulinic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 2 | [1] | |
| Company |
Panacos
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C36H56O6
|
|||
| Canonical SMILES |
CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O
|
|||
| InChI |
1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1
|
|||
| InChIKey |
YJEJKUQEXFSVCJ-WRFMNRASSA-N
|
|||
| CAS Number |
CAS 174022-42-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:65484
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus GAG protein (HIV gag) | Target Info | Inhibitor | [2] |
| Reactome | Uncoating of the HIV Virion | |||
| Budding and maturation of HIV virion | ||||
| Integration of provirus | ||||
| Early Phase of HIV Life Cycle | ||||
| Minus-strand DNA synthesis | ||||
| Plus-strand DNA synthesis | ||||
| 2-LTR circle formation | ||||
| Binding and entry of HIV virion | ||||
| Membrane binding and targetting of GAG proteins | ||||
| Assembly Of The HIV Virion | ||||
| Integration of viral DNA into host genomic DNA | ||||
| Autointegration results in viral DNA circles | ||||
| APOBEC3G mediated resistance to HIV-1 infection | ||||
| Vpr-mediated nuclear import of PICs | ||||
| WikiPathways | Host Interactions of HIV factors | |||
| HIV Life Cycle | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00967187) Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.. U.S. National Institutes of Health. | |||
| REF 2 | Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.